Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

Summary

This trial is to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab prior to surgical resection in participants with resectable, high-risk, locoregionally advanced, PD-L1-positive squamous cell carcinoma of the head and neck (HNSCC). The names of the study drugs used in this research study are: * ficerafusp alfa (a type of bifunctional antibody and recombinant fusion protein) * pembrolizumab (a type of monoclonal antibody)

Timeline

Start

2026-03-26

Primary completion

2028-04-30

Completion

2030-04-30

Drugs

Indications